Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00953121 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
A Phase 2 study of Malignant Glioma, sponsored by Annick Desjardins.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT00953121: Completed Phase 2 study of Malignant Glioma, sponsored by Annick Desjardins.
NCT00953121 is a Phase 2 study of Malignant Glioma that has completed, run by Annick Desjardins. The registered enrollment target is 104 participants, above the 89-participant average among 40 other Malignant Glioma trials with a reported enrollment target (17% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00953121, a Phase 2 study of Malignant Glioma, has completed, sponsored by Annick Desjardins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether Bevacizumab, CPT-11 and Carboplatin in combination are effective in the treatment of recurrent malignant glioma.
Primary Outcome
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Response Assessment in Neuro-Oncology (RANO) criteria, or to death due to any cause. Progression is defined as greater than or equal to a 25% increase in the product of the largest perpendicular diameters of any enhancing lesion or any new enhancing
Conditions Studied
Interventions
- DRUG bevacizumab and CPT-11 and Carboplatin
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
What the finished NCT00953121 record still lists
NCT00953121 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, above the 89-participant average among 40 other Malignant Glioma trials with a reported enrollment target (17% higher).
The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 1 intervention - of which bevacizumab and CPT-11 and Carboplatin is the first listed.
NCT00953121 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00953121 about?
NCT00953121 is a clinical study titled "Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)". The purpose of this study is to determine whether Bevacizumab, CPT-11 and Carboplatin in combination are effective in the treatment of recurrent malignant glioma.
What is the current status of trial NCT00953121?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2009-09. Estimated completion is 2013-01.
What conditions does trial NCT00953121 study?
This clinical trial studies the following conditions: Malignant Glioma.
What interventions are being tested in trial NCT00953121?
The interventions under investigation include: bevacizumab and CPT-11 and Carboplatin (DRUG).
Who is sponsoring clinical trial NCT00953121?
This trial is sponsored by Annick Desjardins, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00953121 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00953121's enrollment target sits among peer trials
104 6th of 40 higher than 35 of 40 other Malignant Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
ACTIVE NOT RECRUITING · Phase 2
-
Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.
ACTIVE NOT RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
ACTIVE NOT RECRUITING · Phase 2
-
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia